Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078772766> ?p ?o ?g. }
- W2078772766 endingPage "1514" @default.
- W2078772766 startingPage "1508" @default.
- W2078772766 abstract "ObjectiveLong-term results of surgical vessel reconstruction are compromised by restenosis caused by neointimal hyperplasia. Recent studies suggest that reduced cyclic guanosine monophosphate signaling is associated with neointima formation. In a rat model of endarterectomy, we investigated the effect of pharmacologic inhibition of cyclic guanosine monophosphate degradation on neointima formation by using the selective phosphodiesterase-5 inhibitor vardenafil.MethodsCarotid endarterectomy was performed in male Sprague–Dawley rats by means of incision of the right common carotid artery with removal of intima. Four groups were studied: unoperated control rats (n = 4), sham-operated rats (n = 9), control rats with endarterectomy (n = 9), or endarterectomized rats treated with vardenafil (10 mg/kg/day) postoperatively (n = 9). After 3 weeks, vessel compartment areas were measured by means of conventional microscopy with hematoxylin and eosin staining. Immunohistochemical analysis was performed to confirm neointima formation and the local cyclic guanosine monophosphate content. Plasma levels of cyclic guanosine monophosphate were determined by means of enzyme immunoassay. Student's t test was used for statistical evaluation.ResultsImmunohistochemical analysis demonstrated intensive staining for transforming growth factor β1 and α-smooth muscle actin in the control neointima. Vardenafil significantly reduced the stenosis grade (24.64% ± 7.46% vs 54.12% ± 10.30% in the control group, P < .05) and expression of transforming growth factor β1, as well as α-smooth muscle actin, in the neointima. The immunohistochemical score for cyclic guanosine monophosphate was higher in the treated neointima (4.80 ± 0.76 vs 2.84 ± 0.40 in the control group, P < .05), and increased plasma cyclic guanosine monophosphate levels were found by means of enzyme immunoassay as well (84.65 ± 12.77 pmol/mL vs 43.50 ± 3.30 pmol/mL in the control group, P < .05).ConclusionsTreatment with vardenafil can be considered a new possibility to prevent neointimal hyperplasia after endarterectomy. Long-term results of surgical vessel reconstruction are compromised by restenosis caused by neointimal hyperplasia. Recent studies suggest that reduced cyclic guanosine monophosphate signaling is associated with neointima formation. In a rat model of endarterectomy, we investigated the effect of pharmacologic inhibition of cyclic guanosine monophosphate degradation on neointima formation by using the selective phosphodiesterase-5 inhibitor vardenafil. Carotid endarterectomy was performed in male Sprague–Dawley rats by means of incision of the right common carotid artery with removal of intima. Four groups were studied: unoperated control rats (n = 4), sham-operated rats (n = 9), control rats with endarterectomy (n = 9), or endarterectomized rats treated with vardenafil (10 mg/kg/day) postoperatively (n = 9). After 3 weeks, vessel compartment areas were measured by means of conventional microscopy with hematoxylin and eosin staining. Immunohistochemical analysis was performed to confirm neointima formation and the local cyclic guanosine monophosphate content. Plasma levels of cyclic guanosine monophosphate were determined by means of enzyme immunoassay. Student's t test was used for statistical evaluation. Immunohistochemical analysis demonstrated intensive staining for transforming growth factor β1 and α-smooth muscle actin in the control neointima. Vardenafil significantly reduced the stenosis grade (24.64% ± 7.46% vs 54.12% ± 10.30% in the control group, P < .05) and expression of transforming growth factor β1, as well as α-smooth muscle actin, in the neointima. The immunohistochemical score for cyclic guanosine monophosphate was higher in the treated neointima (4.80 ± 0.76 vs 2.84 ± 0.40 in the control group, P < .05), and increased plasma cyclic guanosine monophosphate levels were found by means of enzyme immunoassay as well (84.65 ± 12.77 pmol/mL vs 43.50 ± 3.30 pmol/mL in the control group, P < .05). Treatment with vardenafil can be considered a new possibility to prevent neointimal hyperplasia after endarterectomy." @default.
- W2078772766 created "2016-06-24" @default.
- W2078772766 creator A5018624537 @default.
- W2078772766 creator A5026657861 @default.
- W2078772766 creator A5033885611 @default.
- W2078772766 creator A5067138756 @default.
- W2078772766 creator A5069419660 @default.
- W2078772766 creator A5072582612 @default.
- W2078772766 creator A5073141203 @default.
- W2078772766 creator A5079835977 @default.
- W2078772766 creator A5090866067 @default.
- W2078772766 date "2009-06-01" @default.
- W2078772766 modified "2023-10-18" @default.
- W2078772766 title "Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy" @default.
- W2078772766 cites W1593956785 @default.
- W2078772766 cites W1964683861 @default.
- W2078772766 cites W1979575429 @default.
- W2078772766 cites W1984939573 @default.
- W2078772766 cites W1993234999 @default.
- W2078772766 cites W1994807255 @default.
- W2078772766 cites W2001406260 @default.
- W2078772766 cites W2003283625 @default.
- W2078772766 cites W2028272091 @default.
- W2078772766 cites W2034587517 @default.
- W2078772766 cites W2040205891 @default.
- W2078772766 cites W2061890470 @default.
- W2078772766 cites W2075437236 @default.
- W2078772766 cites W2086964926 @default.
- W2078772766 cites W2094782470 @default.
- W2078772766 cites W2099574788 @default.
- W2078772766 cites W2101093001 @default.
- W2078772766 cites W2102548815 @default.
- W2078772766 cites W2123282638 @default.
- W2078772766 cites W2133970318 @default.
- W2078772766 cites W2139478233 @default.
- W2078772766 cites W2149407335 @default.
- W2078772766 cites W2151302132 @default.
- W2078772766 cites W2157209694 @default.
- W2078772766 cites W2160307156 @default.
- W2078772766 cites W2163571423 @default.
- W2078772766 cites W2168300710 @default.
- W2078772766 cites W2170187489 @default.
- W2078772766 cites W2767911074 @default.
- W2078772766 doi "https://doi.org/10.1016/j.jtcvs.2008.10.016" @default.
- W2078772766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19464472" @default.
- W2078772766 hasPublicationYear "2009" @default.
- W2078772766 type Work @default.
- W2078772766 sameAs 2078772766 @default.
- W2078772766 citedByCount "16" @default.
- W2078772766 countsByYear W20787727662012 @default.
- W2078772766 countsByYear W20787727662013 @default.
- W2078772766 countsByYear W20787727662014 @default.
- W2078772766 countsByYear W20787727662015 @default.
- W2078772766 countsByYear W20787727662023 @default.
- W2078772766 crossrefType "journal-article" @default.
- W2078772766 hasAuthorship W2078772766A5018624537 @default.
- W2078772766 hasAuthorship W2078772766A5026657861 @default.
- W2078772766 hasAuthorship W2078772766A5033885611 @default.
- W2078772766 hasAuthorship W2078772766A5067138756 @default.
- W2078772766 hasAuthorship W2078772766A5069419660 @default.
- W2078772766 hasAuthorship W2078772766A5072582612 @default.
- W2078772766 hasAuthorship W2078772766A5073141203 @default.
- W2078772766 hasAuthorship W2078772766A5079835977 @default.
- W2078772766 hasAuthorship W2078772766A5090866067 @default.
- W2078772766 hasBestOaLocation W20787727661 @default.
- W2078772766 hasConcept C126322002 @default.
- W2078772766 hasConcept C134018914 @default.
- W2078772766 hasConcept C142724271 @default.
- W2078772766 hasConcept C2776768464 @default.
- W2078772766 hasConcept C2777339539 @default.
- W2078772766 hasConcept C2777562237 @default.
- W2078772766 hasConcept C2778095995 @default.
- W2078772766 hasConcept C2778283817 @default.
- W2078772766 hasConcept C2778583881 @default.
- W2078772766 hasConcept C2778822586 @default.
- W2078772766 hasConcept C2780816001 @default.
- W2078772766 hasConcept C2780994212 @default.
- W2078772766 hasConcept C519581460 @default.
- W2078772766 hasConcept C71924100 @default.
- W2078772766 hasConceptScore W2078772766C126322002 @default.
- W2078772766 hasConceptScore W2078772766C134018914 @default.
- W2078772766 hasConceptScore W2078772766C142724271 @default.
- W2078772766 hasConceptScore W2078772766C2776768464 @default.
- W2078772766 hasConceptScore W2078772766C2777339539 @default.
- W2078772766 hasConceptScore W2078772766C2777562237 @default.
- W2078772766 hasConceptScore W2078772766C2778095995 @default.
- W2078772766 hasConceptScore W2078772766C2778283817 @default.
- W2078772766 hasConceptScore W2078772766C2778583881 @default.
- W2078772766 hasConceptScore W2078772766C2778822586 @default.
- W2078772766 hasConceptScore W2078772766C2780816001 @default.
- W2078772766 hasConceptScore W2078772766C2780994212 @default.
- W2078772766 hasConceptScore W2078772766C519581460 @default.
- W2078772766 hasConceptScore W2078772766C71924100 @default.
- W2078772766 hasIssue "6" @default.
- W2078772766 hasLocation W20787727661 @default.
- W2078772766 hasLocation W20787727662 @default.
- W2078772766 hasLocation W20787727663 @default.
- W2078772766 hasOpenAccess W2078772766 @default.